Foundation News » Retinitis Pigmentosa
UPDATED: Participants Recruited for Valproic Acid Clinical Trial
|
The National Eye Evaluation and Research network (NEER), the clinical trial network of the Foundation Fighting Blindness, is now recruiting participants for a Phase II clinical trial of valproic acid to evaluate the drug’s effectiveness in slowing vision loss for people with autosomal dominant forms of retinitis pigmentosa (adRP).
Valproic acid is already FDA-approved for the treatment of some seizure disorders. Preclinical and clinical research has yielded evidence suggesting that valproic acid may also slow vision loss in people with adRP. (Update) At this time, two sites are enrolling at total of 90 participants for this study--Retina Foundation of the Southwest in Dallas, TX and the University of Utah in Salt Lake City, UT. Participants are required to visit one of the two clinical trial centers approximately six times during the trial, including an initial screening, baseline testing, and four follow-up appointments. Visual field will be the primary outcome measured for the study. Visit www.clinicaltrials.gov for more information about the study, including inclusion and exclusion criteria and clinical trial center contact information. (Search “retinitis pigmentosa” and “valproic acid” or the study identifier NCT01233609) |
Recent Retinitis Pigmentosa Articles
- Retinal Symposium Focuses on Research and Financial Partnerships for Advancing Therapies
- Bone Marrow Stem Cells in Clinical Trial for Retinal Diseases
- GenSight Receives $41.3 Million for Ocular Gene Therapy Development
- Stem Cell Pioneers Creating Retinal Patch to Restore Vision
- XLRS Natural History Study Beginning in Portland, Oregon
